状細胞血管病変を標的とした新しい小分子療法薬の進化
Gregory J Kato1, Mark T Gladwin
1Critical Care Medicine Department, Clinical Center, National Institutes of Health, 10 Center Dr, MSC 1476, Bldg 10-CRC, Room 5-5140, Bethesda, MD 20892-1476, USA. gkato@mail.nih.gov
シークル細胞病は,血解に関連した血管病を引き起こす可能性があり,酸化窒素の欠乏と血管機能障害につながる. この症候群は脳卒中,足の潰瘍,肺高血圧で表れ,新しい治療戦略を促しています.
科学分野:
- 血管生物学 血管生物学
- 血液学 ヘマトロジ
- 病理生理学 病理生理学とは
背景:
- シックル細胞病 (SCD) は慢性的な血解によって特徴付けられます.
- 血液溶解は,酸化窒素 (NO) を取り除き,内皮機能障害に寄与する.
さらに関連する動画
08:23Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
08:04In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
関連する概念動画
Gene Therapy
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
iPS Cell Differentiation
Pharmacogenomics: Identification of New Drug Targets
Microorganisms in Medicine and Therapeutics
